Hebei Daan Pharmaceutical

About Hebei Daan Pharmaceutical

Established in 2004, Hebei Daan Pharmaceutical Co., Ltd. is a privately-held biopharmaceutical firm operating as a subsidiary within a larger corporate structure. The company has carved out a specific niche within the Chinese pharmaceutical market, focusing on the development and production of plasma-derived products that address critical needs in hematological and immunological disorders. Its operations are based in the Hebei province of China.

The core of Hebei Daan's business revolves around its portfolio of therapeutic biological products. The company manufactures Human Coagulation Factor VIII, a crucial treatment for patients with hemophilia A, and Human Prothrombin Complex, which is used for individuals with hemophilia B. Another key product is Human Immunoglobulin (pH4), an intravenous therapy for treating immune thrombocytopenia (ITP) and other immune system deficiencies. The business model is centered on the production and sale of these specialized biopharmaceuticals to healthcare providers and institutions. The revenue stream is directly tied to the commercialization of its product pipeline.

A significant indicator of the company's technical and clinical capabilities is its record of successfully advancing products through late-stage development. Hebei Daan has completed several Phase 3 clinical trials, a critical milestone for any pharmaceutical entity. These trials have validated the efficacy and safety of its primary products, including a single-arm, multicenter trial for its Human Coagulation Factor VIII and a similar late-stage study for its Human Prothrombin Complex. Furthermore, the company has an active New Drug Application (NDA)/Biologics License Application (BLA) under review, signaling its progression towards bringing new therapies to market.